StockData
TherapeuticsMD, Inc. logo

TherapeuticsMD, Inc. (TXMD) stock

TXMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 12/3026% below fair value
$1.81−0.10 (-5.24%)

Close on Nov 18, 2026Market cap $20.95MP/E –Yield –

TherapeuticsMD net income

Net income is the profit left for shareholders after every expense, interest and tax.

TherapeuticsMD's net income for the twelve months ending Jun 30, 2026 was -$217.00K. For fiscal 2025 it was -$569.00K. The highest annual figure on record is $112.00M in fiscal 2022.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$569.00K–
FY2024Dec 31, 2024-$2.18M–
FY2023Dec 31, 2023-$10.28M-109.2%
FY2022Dec 31, 2022$112.00M–
FY2021Dec 31, 2021-$172.42M–
FY2020Dec 31, 2020-$183.52M–
FY2019Dec 31, 2019-$176.15M–
FY2018Dec 31, 2018-$132.62M–
FY2017Dec 31, 2017-$76.93M–
FY2016Dec 31, 2016-$89.88M–
FY2015Dec 31, 2015-$85.08M–
FY2014Dec 31, 2014-$54.22M–
FY2013Dec 31, 2013-$28.42M–
FY2012Dec 31, 2012-$35.12M–
FY2011Dec 31, 2011-$12.91M–
FY2010Dec 31, 2010-$2.87M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$155.00K-71.9%
Q1 FY2026Mar 31, 2026$95.00K–
Q4 FY2025Dec 31, 2025-$619.00K-345.6%
Q3 FY2025Sep 30, 2025$152.00K–
Q2 FY2025Jun 30, 2025$551.00K–
Q1 FY2025Mar 31, 2025-$653.00K–
Q4 FY2024Dec 31, 2024$252.00K–
Q3 FY2024Sep 30, 2024-$609.00K–
Q2 FY2024Jun 30, 2024-$1.09M–
Q1 FY2024Mar 31, 2024-$734.00K–
Q4 FY2023Dec 31, 2023-$883.00K-101.1%
Q3 FY2023Sep 30, 2023-$3.38M–
Q2 FY2023Jun 30, 2023-$2.41M-102.1%
Q1 FY2023Mar 31, 2023-$3.60M–
Q4 FY2022Dec 31, 2022$77.70M–
Q3 FY2022Sep 30, 2022-$28.97M–
Q2 FY2022Jun 30, 2022$112.28M–
Q1 FY2022Mar 31, 2022-$49.02M–
Q4 FY2021Dec 31, 2021-$42.96M–
Q3 FY2021Sep 30, 2021-$47.42M–
Q2 FY2021Jun 30, 2021-$42.65M–
Q1 FY2021Mar 31, 2021-$39.38M–
Q4 FY2020Dec 31, 2020-$42.09M–
Q3 FY2020Sep 30, 2020-$32.61M–
Q2 FY2020Jun 30, 2020-$51.98M–
Q1 FY2020Mar 31, 2020-$56.85M–
Q4 FY2019Dec 31, 2019-$49.44M–
Q3 FY2019Sep 30, 2019-$31.97M–
Q2 FY2019Jun 30, 2019-$55.24M–
Q1 FY2019Mar 31, 2019-$39.51M–
Q4 FY2018Dec 31, 2018-$39.39M–
Q3 FY2018Sep 30, 2018-$35.61M–
Q2 FY2018Jun 30, 2018-$33.22M–
Q1 FY2018Mar 31, 2018-$24.40M–
Q4 FY2017Dec 31, 2017-$21.43M–
Q3 FY2017Sep 30, 2017-$14.67M–
Q2 FY2017Jun 30, 2017-$19.68M–
Q1 FY2017Mar 31, 2017-$21.16M–
Q4 FY2016Dec 31, 2016-$22.84M–
Q3 FY2016Sep 30, 2016-$25.02M–

More TherapeuticsMD figures

See a number that looks wrong?